Proprotein Convertase Subtilisin/Kexin Type 9 Market Size, Share, Industry, Forecast and outlook (2023-2030)
Published: 2024 February 02
SKU : PH4249
180 pages
Report Summary
Table of Contents
List of Tables & Figures
Buy this report
Single User
$4350
Multiple User
$4850
Enterprise User
$7850
Request new version
FAQ’s
What is the Proprotein Convertase Subtilisin/Kexin Type 9 Market?
The Proprotein Convertase Subtilisin/Kexin Type 9 Market refers to the market for drugs targeting PCSK9, an enzyme linked to high cholesterol and cardiovascular diseases. This market is anticipated to grow significantly due to factors like rising prevalence of heart disease, increasing awareness, and new drug approvals.
Which companies are the major players in the PCSK9 inhibitor market?
Some of the key players include Amgen, Novartis, Regeneron Pharmaceuticals, Sanofi, and Dicerna Pharmaceuticals.